CM Hospitalar (VVEO3) Q2 2024 earnings summary

Executive summary

• Focus on operational excellence, cost reduction, deleveraging, and inventory adjustment following integration challenges and margin pressures.

• Service levels and supply chain performance improved, with further gains expected as excess inventory is reduced.

• Strategic initiatives include centralizing distribution, optimizing production, automation, and simplifying organizational structure.

• Emphasis on cash generation, working capital optimization, and disciplined capital allocation, with governance enhancements and new board members.

• Management expects profitability and robust cash generation to recover by year-end.

Financial highlights

• Net revenue reached R$2,753.5M in 2Q24 (up 8.7% YoY) and R$5,711.7M in 1H24 (up 7.1% YoY).

• Free cash flow was R$313.8M in 2Q24 (vs R$232.8M in 2Q23) and R$142.0M in 1H24 (vs -R$491.6M in 1H23).

• 2Q24 gross margin: 14.4% (-3.5pp YoY); adjusted EBITDA: R$171.3M (margin 6.2%, -3.7pp YoY).

• Adjusted net loss was R$5.2M in 2Q24; reported net loss R$87.7M.

• ROIC stood at 11.4%.

Outlook and guidance

• Further cost reductions, margin improvements, and efficiency gains expected from Q4 2024 onward as restructuring and automation take effect.

• Inventory reduction and working capital improvements targeted for 2H24.

• Centralization of operations in strategic distribution centers to improve service and cost competitiveness from 3Q24 and 1Q25.

• Profitability and cash generation expected to visibly recover by year-end, aiming for 2022–2023 levels by 2025.